Therapeutic potential of microRNAs in heart failure.
There is an ongoing explosion of information about microRNAs (miRs) in cardiac disease. These small noncoding RNAs regulate protein expression by destabilization and translational inhibition of target mRNAs. Similar to mRNAs, miRs are regulated in cardiac hypertrophy and heart failure, but miR expression profiles appear to be more sensitive than mRNA signatures to changes in clinical status, suggesting that miR levels in myocardium or plasma could enhance clinical diagnostics. Single miRs can target dozens or hundreds of different mRNAs, complicating attempts to determine their individual physiologic effects. However, manipulating individual miRs by overexpression or gene ablation in experimental models has begun to unravel this conundrum: Single miRs tend to regulate numerous effectors within the same functional pathway, producing a coherent physiologic response via multiple parallel perturbations. miRs are attractive nodal therapeutic targets, and stable miR mimetics (agomiRs) and antagonists (antagomiRs) are being evaluated to prevent or reverse heart failure.
Dorn
Gerald W
GW
Washington University Center for Pharmacogenomics, 660 South Euclid Avenue, Campus Box 8220, St. Louis, MO 63110, USA. gdorn@dom.wustl.edu
D006332:Cardiomegaly / Q000503:physiopathology / Q000628:therapy; D005355:Fibrosis / Q000503:physiopathology / Q000628:therapy; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D035683:MicroRNAs; D009206:Myocardium / Q000473:pathology; D032383:Myocytes, Cardiac / Q000473:pathology; D012333:RNA, Messenger
D035683:MicroRNAs; D012333:RNA, Messenger